Dysregulation of histone-modifying enzymes, including HDACs, histone acetyltransferases (HATs), and histone methyltransferases, contributes to oncogene activation and tumor suppressor silencing, processes that are closely linked to the development of resistance to chemotherapy and targeted therapies. The gene discussed is PRDM9; the disease is neoplasm.